Financial Performance - The company's revenue for Q1 2025 was ¥471,967,670.63, representing a decrease of 9.94% compared to ¥524,066,868.93 in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of ¥26,901,607.29, a decline of 134.03% from a profit of ¥79,061,260.62 in Q1 2024[5]. - Total operating revenue for the current period was ¥471,967,670.63, a decrease of 9.9% compared to ¥524,066,868.93 in the previous period[22]. - The company reported a net profit of -142,361,032.21 yuan for the current period, compared to a net profit of 29,961,530.26 yuan in the previous period, indicating a significant decline[23]. - Operating profit for the current period was -126,574,064.46 yuan, while the previous period showed an operating profit of 56,155,547.90 yuan, reflecting a substantial decrease[23]. - The total comprehensive income for the current period was -142,313,442.07 yuan, compared to 29,589,098.69 yuan in the previous period[23]. - Basic and diluted earnings per share for the current period were both -0.0192 yuan, down from 0.0676 yuan in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥86,799,597.52, a 91.10% reduction compared to a net outflow of ¥975,365,408.34 in the previous year[12]. - Cash and cash equivalents at the end of the period reached ¥1,298,752,857.02, up 48.9% from ¥872,081,872.91 at the beginning of the period[19]. - The company reported cash and cash equivalents at the end of the period amounting to 1,298,752,857.02 yuan, a decrease from 2,686,302,001.07 yuan at the end of the previous period[26]. - The company generated cash inflow from investment activities amounting to 472,270,137.70 yuan, with a net cash flow from investment activities of 361,108,752.50 yuan[26]. - The company recorded a total operating cash inflow of 443,386,291.36 yuan, down from 576,280,891.81 yuan in the previous period[25]. - The company received 163,000,000.00 yuan from financing activities, resulting in a net cash flow from financing activities of 163,000,000.00 yuan[26]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥6,092,264,108.12, reflecting a 1.16% increase from ¥6,022,115,755.32 at the end of the previous year[5]. - Total assets increased to ¥6,092,264,108.12, compared to ¥6,022,115,755.32 at the beginning of the period, reflecting a growth of 1.2%[20]. - Total liabilities rose to ¥1,734,625,266.13, an increase of 13.7% from ¥1,526,185,458.97 in the previous period[20]. - The company's total equity decreased to ¥4,357,638,841.99 from ¥4,495,930,296.35, a decline of 3.1%[21]. - The company’s total equity attributable to shareholders decreased by 0.66% to ¥3,705,741,472.18 from ¥3,730,544,275.59 at the end of the previous year[5]. Research and Development - Research and development expenses surged by 117.68% to ¥240,479,825.00 in Q1 2025, up from ¥110,476,228.75 in Q1 2024, due to multiple products being in clinical development[11]. - Research and development expenses surged to ¥240,479,825.00, representing a significant increase from ¥110,476,228.75 in the previous period[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,564[14]. - The largest shareholder, Shijiazhuang Yiling Pharmaceutical Co., Ltd., holds 73.77% of shares, totaling 1,036,159,894 shares[14]. - The company has 157,520,510 restricted shares held by Shijiazhuang Yiling Pharmaceutical Co., Ltd., which are subject to a 36-month transfer restriction[16]. - The total number of shares held by the top 10 unrestricted shareholders is 878,639,384 shares[14]. - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[15]. - The company has not reported any changes in the number of preferred shareholders or their holdings[15]. - The company’s stock structure includes various institutional investors, with the top 10 shareholders holding a significant portion of the shares[14]. - The company’s financial disclosures indicate a commitment to transparency regarding shareholder relationships and potential risks associated with stock transfers[17]. Acquisition Plans - The company plans to acquire 100% equity of Shijiazhuang Baike Biopharmaceutical Co., Ltd. through a combination of cash and stock issuance, with the transaction currently under review by the Shenzhen Stock Exchange[17]. - The company will continue to provide updates on the acquisition process as it progresses through regulatory reviews[17].

新诺威（300765）公告，2025年第一季度营收为4.72亿元，同比下降9.94%；净亏损2690.16万元，去年 同期净利润7906.13万元。 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.6127 yuan, reflecting a growth of 2.27% [1] - The fund's one-month return is 14.21%, ranking 9th out of 4672 similar funds; the three-month return is 36.72%, ranking 18th out of 4599; and the year-to-date return is 34.02%, ranking 36th out of 4590 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with significant positions in companies such as Heng Rui Pharmaceutical (9.81%), Innovent Biologics (8.55%), and others [1] - The fund was established on November 13, 2019, and as of December 31, 2024, it has a total scale of 2.02 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry since 2022 [2]

Core Viewpoint - The recent performance of the Zhongyin Innovation Medical Mixed A fund shows a decline in net value but strong returns over various time frames, indicating potential resilience in the healthcare investment sector [1]. Fund Performance Summary - The latest net value of Zhongyin Innovation Medical Mixed A is 1.5786 yuan, down by 2.81% - The fund's one-month return is 13.30%, ranking 7 out of 4623 in its category - The three-month return stands at 38.74%, ranking 14 out of 4566 - Year-to-date return is 31.19%, ranking 24 out of 4559 [1]. Holdings Summary - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with the following key positions: - Heng Rui Pharmaceutical: 9.81% - Xinda Bio: 8.55% - Huaneng Pharmaceutical: 8.41% - Kangfang Biotech: 8.35% - Kangnuo Ya-B: 8.32% - Kelun Botai: 7.87% - BeiGene-U: 6.24% - Rongchang Bio: 5.96% - Hansoh Pharmaceutical: 3.98% - Xin Nuo Wei: 3.11% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and extensive experience in the investment sector, having previously worked at Taikang Asset Management and Zhonggeng Fund Management - Zheng joined Zhongyin Fund Management in 2022 and has managed multiple funds since then, including the Zhongyin Innovation Medical Mixed Fund [2].

证券代码：300765 证券简称：新诺威 公告编号：2025-035 石药创新制药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议的情形。 一、会议的召开和出席情况 1. 股东大会的届次：2024 年年度股东大会。 2. 会议召集人：公司董事会。 3. 会议主持人：公司董事长姚兵。 4. 会议召开的日期、时间： 5. 现场会议召开地点：河北省石家庄市高新区中山东路 896 号公司会议室。 6. 出席会议的股东人数： 通过现场和网络投票的股东 228 人，代表股份 1,166,030,551 股，占公司有 表决权股份总数的 83.7309％。 其中：通过现场投票的股东 3 人，代表股份 1,047,747,206 股，占公司有表 决权股份总数的 75.2372％。 通过网络投票的股东 225 人，代表股份 118,283,345 股，占公司有表决权股 份总数的 8.4938％。 1 本次会议符合《中华人民共和国 ...

新诺威（300765）公告，控股子公司巨石生物申报的SYS6041注射剂临床试验申请已获得美国FDA批 准，可以在美国开展临床试验。该药物是一款单克隆抗体偶联药物，适用于晚期实体瘤，已在国内外提 交多件专利申请。此前，该产品已于2025年1月获得中国国家药品监督管理局批准，可以在中国开展临 床试验。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-034 石药创新制药股份有限公司 关于控股子公司 SYS6041 抗体偶联药物 获得美国药物临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、概述 剂 型：注射剂 申请事项：临床试验 IND 编号：175990 申请人：石药集团巨石生物制药有限公司 审批结论：根据《联邦食品、药品和化妆品法案》(FDCA)第 505(i)规定递 交的 SYS6041 临床研究申请(IND)，通过美国 FDA 的安全性审查并认为巨石生 物可开展针对晚期实体瘤的临床研究。 三、药物的其他相关情况 SYS6041 是一款单克隆抗体偶联药物，可与肿瘤表面的特异性受体结合， 通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用。本次获批临床 的适应症为晚期实体瘤。临床前研究显示，SYS6041 对多种癌症均有较好的抗 肿瘤作用，具有较高的临床开发价值。该产品已在国内外提交多件专利申请。 1 此前，该产品已经于 2025 年 1 月获得中华人民共和国国家药品监督管理局 批准，可以在中国开展临床试验。具体内 ...

Group 1: Production and Market Strategy - The company has a caffeine production capacity of 16,700 tons/year, with a sales volume of 14,010 tons in 2023. It aims to enhance gross margins through product structure upgrades and explore new application fields such as medical beauty and pet health [1] - The company is committed to maintaining its competitive edge in the functional raw materials industry by expanding into niche products like theobromine and theophylline, leveraging its production advantages to create a diversified profit engine [1] Group 2: Research and Development - The company emphasizes innovation and R&D as core drivers for future growth, focusing on aligning product development with market demand to mitigate the high failure rates and costs associated with drug development [2] - Significant resources are being allocated to accelerate product layout and R&D progress, with a goal to solidify and expand its innovative biopharmaceutical platform [2] Group 3: Financial Performance and Shareholder Information - As of April 10, 2025, the number of shareholders is 10,386 [4] - The company plans to disclose its Q1 2025 report on April 24, 2025, and has already released its 2024 annual report on March 21, 2025 [4] Group 4: Market Impact and Risk Management - The direct revenue from the U.S. market is low, and the current tariff policies have minimal direct impact on the company's profitability, indicating manageable risk [4] - The company is actively monitoring changes in international trade policies to address potential risks [4] Group 5: Product Development and Sales - The company is in the process of commercializing the innovative drugs Enlansumab and Omabuzumab, which have been approved for inclusion in the medical insurance directory [5] - The sales network for these products is being developed systematically [5]